tp-1454 monotherapy
Anal Cancer
Sumitomo Pharma America, Inc.Phase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 73/ 100
Competitive context
46 Active assets in the Anal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Federation Francophone de Cancerologie Digestive | Phase 3 | BB |
Carboplatin Dustin Deming | Phase 3 | BB |
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 3 | BB |
Irinotecan University of Cincinnati | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Federation Francophone de Cancerologie Digestive | Phase 3 | BB |
View all 50 →
Same molecule, other indications
tp-1454 monotherapy is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →